TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01895452
Drug: ALKS 9072, Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, given monthly
Study: NCT01895452
Drug: ALKS 9072, High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, given monthly
Study: NCT02709928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03783728
Drug: Pyridoxine 50 mg orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a week for 12 weeks using Video Directly Observed Therapy
Study: NCT02909569
Drug: INCB039110
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
Study: NCT03341910
Drug: DFD-03 Lotion, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
Study: NCT03341910
Drug: Tazorac Cream, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
Study: NCT03341910
Drug: DFD-03 Vehicle Lotion 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
Study: NCT03341910
Drug: Tazorac Vehicle Cream 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
Study: NCT02358369
Drug: Placebo Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops BID OU.
Study: NCT02760017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03655717
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
Study: NCT03655717
Drug: Placebo ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
Study: NCT00999219
Drug: FK199B
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04398199
Drug: Hypofractionated Radiation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
Study: NCT01884857
Drug: 'TOPROL-XL®' ER Tablets 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 \* 50 mg tablet per day
Study: NCT01810302
Drug: Preservative-free normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Study: NCT03001843
Drug: Narcotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The narcotic group will receive no ketamine but rather a more standard anesthetic
Study: NCT01098838
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01681576
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400mg tablet once daily
Study: NCT04138043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
Study: NCT04138043
Drug: GSK2330811
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330811 will be available as SC injection 150 mg/mL.
Study: NCT02435732
Drug: Placebo saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT02435732
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added to the one of the arms receiving 200U/kg dose of CINRYZE
Study: NCT03584087
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG 0 (0Hr)
Study: NCT03368131
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825\~1000mg/m2 bid d1-14
Study: NCT01522040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple saline drip, without active drug
Study: NCT00546039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03603834
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles
Study: NCT00587860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
Study: NCT00115700
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 I.V. on day 1
Study: NCT00115700
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 orally daily for days 1 - 5
Study: NCT00995670
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
Study: NCT00258206
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01928485
Drug: Sunphenon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04111107
Drug: Investigational Agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
Study: NCT01464242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400mg orally 3 times a day for 20 days
Study: NCT03512977
Drug: conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
Study: NCT03011450
Drug: Placebo (for K-877)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02907320
Drug: placebo MPFF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01212770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03717961
Drug: BOTOX® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
Study: NCT03717961
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
Study: NCT02483169
Drug: Placebo of aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: same size and shape of active aspirin 100mg
Study: NCT01214772
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
Study: NCT01093729
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C 0.5mcg/kg or Placebo
Study: NCT01093729
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C 2mcg/kg or Placebo
Study: NCT01093729
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C 4mcg/kg or Placebo
Study: NCT01093729
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C 8mcg/kg or Placebo
Study: NCT01093729
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C 14mcg/kg or Placebo
Study: NCT00838110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TID for week 1 followed by 20 mg TID through Week 26
Study: NCT00838110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
Study: NCT01262651
Drug: Placebo (GA-0034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01088932
Drug: SRX246
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT01843426
Drug: Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
Study: NCT03588533
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: - Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
Study: NCT05630274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01786512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablets matching to omecamtiv mecarbil
Study: NCT02260648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04268472
Drug: GP30101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
Study: NCT04268472
Drug: Prezista®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
Study: NCT03162224
Drug: MEDI0457
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
Study: NCT00760929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 9mg/kg weekly
Study: NCT00760929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 16mg/kg every 3 weeks
Study: NCT00760929
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 9mg/kg weekly
Study: NCT00760929
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 16mg/kg every 3 weeks
Study: NCT02634411
Drug: 8 days of effective antibiotic treatment
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days.
Study: NCT02206503
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
Study: NCT01733004
Drug: MM-141
Normalized name: inositol 141 MG
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03135951
Drug: SPI-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
Study: NCT02277106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02293902
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispensed according to local practice.
Study: NCT02293902
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dispensed according to local practice.
Study: NCT00411736
Drug: Study medication, azithromycin or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
Study: NCT00411736
Drug: Azithromycin or placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
Study: NCT01008033
Drug: IDP-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 48 weeks
Study: NCT01008033
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day for 48 weeks
Study: NCT02541708
Drug: Ferrous sulfate + folic acid
Normalized name: ferrous sulfate / folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
Study: NCT00574080
Drug: Induction/Consolidation Adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 by continuous infusion Days 1-4
Study: NCT00574080
Drug: InductionConsolidation Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m2 by continuous infusion Days 1-4
Study: NCT00574080
Drug: Transplant 1 Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/m2 by continuous infusion Days -3 and -2
Study: NCT02256423
Drug: REFERENCE 1: Nurofen® 200 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256423
Drug: REFERENCE 2: Ibuprofen 200 mg soft gel capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256423
Drug: ibuprofen 200 mg soft gel capsule
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02491697
Drug: Capecitabine Monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
Study: NCT04428359
Drug: Measles-Mumps-Rubella Vaccine
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
Study: NCT04428359
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
Study: NCT02157506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00794612
Drug: Dermacyd Femina Pocket BR (Lactic Acid)
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
Study: NCT03434951
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
Study: NCT00345241
Drug: Systane Ocular Drops (OTC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345241
Drug: Placebo - Saline Drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784810
Drug: Codeine/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
Study: NCT02085213
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT04061252
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Description: brodalumab 210mg Q2W, SC
Study: NCT04061252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q2W, SC
Study: NCT04260659
Drug: Remifentanil [Ultiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
Study: NCT04260659
Drug: Fentanyl [Fentanyl WZF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
Study: NCT00879606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
Study: NCT05041322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take placebo pills (twice a day) for 14 Days.
Study: NCT02119416
Drug: Placebo Administration first
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
Study: NCT02119416
Drug: Low Caffeine Administration first (1mg/kg body weight)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
Study: NCT02119416
Drug: High Caffeine Administration first (2mg/kg body weight)
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
Study: NCT01575405
Drug: Universal HEC Placebo Gel Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
Study: NCT02965950
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: I.v. infusion
Study: NCT01945606
Drug: Placebo (treatment 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo tablets
Study: NCT02352558
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
Study: NCT02077257
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg/d compared to 10 mg/day
Study: NCT03817424
Drug: VIB7734
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive VIB7734 via injection.
Study: NCT03817424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to VIB7734 via injection.
Study: NCT05008354
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine tablet 40mg once daily
Study: NCT05008354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT01640808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 x Placebo capsules) orally, twice a day
Study: NCT00325650
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT00533377
Drug: CP-533, 536
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study drug
Study: NCT00533377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle
Study: NCT00533377
Drug: CP-533,536
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study drug
Study: NCT00183911
Drug: floxuridine, 5-Fluorouracil, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02921997
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT02401191
Drug: FEX60/PE10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00878631
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ccs of normal saline infused within 4 hours of the accident